NEWS
Astellas join Milner Therapeutics Consortium
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global...
Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful...
Milner collaboration with Harvard University and the Wellcome Sanger Institute uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein...
Milner group use combination of computational biology and machine learning to create comprehensive map of proteins involved in SARS-CoV-2 infection
Namshik Han's group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to...
Connect: Health Tech is launched
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite...
New Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in...
Affiliate Companies showcase their work
As we reach the end of what has been the most challenging and difficult year so far, we want to take the time to celebrate the achievements of our...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the...
Start Codon closes new £15 million venture fund
Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed...
OncoInnovation: TGIO 2020 Challenge winner
Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early...
Kostas Tzelepis awarded John Goldman Fellowship
We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and...
Kathryn Lilley awarded EMBO membership
We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been...
Start Codon announces first cohort of companies
Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were...
Eisai join Milner Therapeutics Consortium
We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading...
Milner Institute illuminated blue for the NHS
The Jeffrey Cheah Biomedical Centre illuminated blue tonight, to honour the incredible work of our NHS. Milner Institute Director Professor Tony...
Milner seminars move online
We have been busy adapting plans for the coming months, and are pleased to announce that our Milner seminars are moving online. The first talk is...
Providing COVID-19 support
Thank you to the numerous Milner affiliated companies who have been in contact to offer support to the University and NHS at this time. Help tackle...
Milner Institute closure for COVID-19
As part of the response to COVID-19 at the University of Cambridge, the Milner Therapeutics Institute will be closed for non-essential business from...